27 October 2026
HARGREAVE HALE AIM VCT PLC
(the “Company”)
NAV announcement
As at close of business on 23 October 2026, the unaudited Net Asset Value (NAV) for Hargreave Hale AIM VCT plc was as follows:
NAV per Ordinary share of 1p – 31.87 pence.
END
For further information, please contact:
| Canaccord Genuity Asset Management Limited Abbe Martineau |
aimvct@canaccord.com +44 20 7523 4525 |
LEI: 213800LRYA19A69SIT31
eQ Plc Managers’ Transactions
27 October 2026 at 3:30 p.m.
Person subject to the notification requirement
Name: Privestment Oy
Position: Closely associated person
(X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer
Name: Jouko Pölönen
Position: Chief Executive Officer
Issuer: eQ Oyj
LEI: 743700R4FA6AVH5J3D68
Notification type: INITIAL NOTIFICATION
Reference number: 177634/10/8
____________________________________________
Transaction date: 2026-10-26
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009009617
Nature of transaction: ACQUISITION
Transaction details
(1): Volume: 3485 Unit price: 8.2 EUR
(2): Volume: 4300 Unit price: 8.2 EUR
(3): Volume: 1184 Unit price: 8.2 EUR
(4): Volume: 329 Unit price: 8.2 EUR
(5): Volume: 2 Unit price: 8.2 EUR
(6): Volume: 113 Unit price: 8.2 EUR
(7): Volume: 587 Unit price: 8.2 EUR
Aggregated transactions (7):
Volume: 10000 Volume weighted average price: 8.2 EUR
eQ Plc
Additional information: Juha Surve, Group General Counsel, tel. +358 9 6817 8733
Distribution: Nasdaq Helsinki, www.eQ.fi
eQ is a Finnish group that concentrates on asset management and Corporate Finance business. eQ Asset Management offers a wide range of asset management services to both institutions and individuals. The assets managed by the Group total approximately EUR 13.9 billion. Advium Corporate Finance, which is part of the Group, offers services related to mergers and acquisitions, real estate transactions and equity capital markets. The parent company eQ Plc’s shares are listed on Nasdaq Helsinki. More information about the Group is available on our website www.eQ.fi.
GOBLET Cohort 4 demonstrates approximately 15-month median duration of response that exceeds historical results for approved second-line checkpoint inhibitor monotherapy
100% of responding patients survived for longer than one year
FDA Fast Track Designation and recent regulatory guidance support advancement toward registration and potential expansion into HPV-driven head and neck cancer
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced updated data from Cohort 4 of its Phase 1/2 GOBLET study evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with second-line or later squamous cell anal cancer (“SCAC”).
Although median overall survival has not yet been reached, the median duration of response is approximately 15 months,1 which compares favorably with historical results of 9.5 months for U.S. Food and Drug Administration (“FDA”)-approved retifanlimab monotherapy in a similar patient population.2 Notably, all patients who responded to treatment survived beyond 12 months, including multiple patients surviving over 24 months.
These results provide encouraging evidence that pelareorep enhanced the clinical benefit of checkpoint inhibition in advanced SCAC, a disease in which more than 90% of cases are associated with human papillomavirus (“HPV”).
“We see anal cancer as the starting point for building a pelareorep plus checkpoint inhibitor platform across HPV-driven cancers,” said Jared Kelly, Chief Executive Officer of Oncolytics. “Our survival data and recent FDA regulatory clarity give us a path to pursue registration in anal cancer while expanding into other HPV-associated tumors, including head and neck cancer, where pelareorep has already demonstrated encouraging clinical activity.”
FDA Pathway Opens Door to Broader HPV Cancer Platform
Following recent FDA interactions and receipt of Fast Track Designation, Oncolytics plans to explore additional clinical studies with a potential checkpoint inhibitor partner to support registrational development in SCAC. The Company believes that durable clinical responses may support an accelerated approval pathway, while overall survival could provide evidence of clinical benefit supporting full approval, subject to FDA agreement.
The Company also sees potential to expand into HPV-associated head and neck squamous cell carcinoma. HPV accounts for approximately 70% of oropharyngeal cancers in the United States, representing a substantial patient population where checkpoint inhibitors are already established therapies.
Pelareorep has previously demonstrated signals of antitumor activity in head and neck cancer studies, although it has not yet been evaluated in combination with a checkpoint inhibitor in this disease. Oncolytics may explore initiating such a combination study in the near term as part of its broader HPV-driven cancer strategy.
About GOBLET
The GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 17 centers in Germany and is being managed by AIO-Studien-gGmbH (“AIO”). The co-primary endpoints of the study are objective response rate and/or disease control rate and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers. The study comprises five treatment groups:
About AIO
AIO emerged from the study center of the medical oncology working group within the German Cancer Society. AIO operates with a non-profit purpose of promoting science and research with a focus on medical oncology. Since its foundation, AIO has become a successful sponsor and study management company and has established itself both nationally and internationally.
About Pelareorep
Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action that selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes. It has been administered to over 1,200 patients, and clinical studies have demonstrated pelareorep’s potential to enhance the activity of checkpoint inhibitors and other anti-cancer therapies across multiple solid tumor types.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically inactive tumors to active through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal, anal, and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on LinkedIn and on X @oncolytics.
Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
References
Forward-looking statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the results, and implication of results, from Cohort 4 of the GOBLET study; the Company’s plans to explore additional clinical studies related to SCAC and its beliefs in their potential benefits; the Company’s possible expansion into HPV-associated head and neck cancer including a study in combination with pelareorep; the Company’s goals, strategies, and objectives; the Company’s belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers; and the Company’s goals and expectations for its potential registrational development path for pelareorep in multiple gastrointestinal cancers. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.com
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be webcasting its participation in the following upcoming investor conferences:
The presentations will be accessible via webcast links on the Investor Events section of the Coherus website: https://investors.coherus.com/events-presentations. Replays of the presentations will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective bank representative.
Disclosure Information
Coherus uses the https://investors.coherus.com website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
About Coherus
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, prostate, head & neck, colorectal and other cancers. The Company’s strategy is to grow sales of LOQTORZI in R/M Nasopharyngeal Carcinoma and advance the development of its two pipeline candidates in combination with LOQTORZI and through strategic partnerships.
Coherus’ innovative oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and improve outcomes for patients with cancer. Tagmokitug is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors; including head and neck squamous cell carcinoma, colorectal cancer, gastric, gastro-esophageal-junction, esophageal adenocarcinoma and esophageal squamous cell carcinoma. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a Phase 2 study in patients with first-line hepatocellular carcinoma.
LOQTORZI® is a registered trademark of Coherus Oncology, Inc.
©2026 Coherus Oncology, Inc. All rights reserved.
Coherus Oncology Contact Information:
For Investors:
Carrie Graham
Vice President, Investor Relations & Advocacy
IR@coherus.com
LITTLE ROCK, Ark., Oct. 27, 2026 (GLOBE NEWSWIRE) — Uniti Wholesale today announced expanded connectivity at nine data center locations across six states, extending access to 100G and 400G wavelength services. The expansion includes new data center presence and upgrades to existing connectivity, helping customers connect critical infrastructure, broaden their network reach, and accommodate growing bandwidth requirements.
The expanded footprint also simplifies network planning, giving customers more options to link data centers across markets through a single connectivity partner.
Alongside the expansion, Uniti Wholesale is launching a campaign featuring promotional offers on select 100G and 400G wavelength routes.
“Our customers need more than bandwidth—they need connectivity that fits their business,” said Greg Ortyl, executive vice president and president of Strategic Accounts for Uniti Wholesale. “This expansion gives them more locations to connect, greater flexibility in planning their networks, and a team they can trust to help bring it together.”
| Data Center Provider | Location | Address |
| Equinix | El Segundo, California | 445 N. Douglas |
| H5 Data Centers | Chandler, Arizona | 2600 W. Germann Road |
| VTX | Laredo, Texas | 520 Matamoros |
| H5 Data Centers | San Antonio, Texas | 100 Taylor Street |
| Fifteenfortyseven | McAllen, Texas | 200 S. 10th Street |
| Flexential | Franklin, Tennessee | 425 Duke Drive |
| Digital Realty | Clifton, New Jersey | 2 Peekay Drive |
| QTS | Piscataway, New Jersey | 101 Possumtown Road |
| CyrusOne | Sterling, Virginia | 21350 Pacific Street |
“A key element in the rapid growth of data center supply is a similar growth trajectory of fiber and communications infrastructure across the United States,” said Josh Simms, CEO of H5 Data Centers. “Uniti Wholesale’s expanded connectivity at each of our Chandler, Arizona, and San Antonio, Texas, data centers can provide customers access to 100 and 400G capacity to support bandwidth-intensive applications and connect their operations across key markets.”
Select 100G and 400G Routes
With approximately 150 route options spanning the West Coast to the East Coast, Uniti Wholesale is giving customers more ways to add high-capacity connectivity at promotional rates.
To take advantage of these exclusive promotional offers, customers can explore eligible routes and view real-time pricing through Route Creator in the Uniti Wholesale iconnect customer portal or contact their sales director for additional details.
Meet With Uniti Wholesale at INCOMPAS
Customers can meet the Uniti Wholesale team at INCOMPAS, Nov. 1–3, 2026, to discuss their connectivity needs and available offers, or contact their Uniti Wholesale representative directly.
About Uniti Wholesale
Uniti Wholesale, a business unit of Uniti (NASDAQ: UNIT), builds and delivers customer-driven dark fiber infrastructure and high-capacity wavelengths, ethernet and wireless access leveraging our optical transport network reaching nearly every hyperscale and AI firm, communications services provider, Fortune 500 enterprise and federal government customers in the U.S. and Canada. Additional information about Uniti Wholesale is available at unitiwholesale.com. Engage with us on LinkedIn.
Media Contact
Scott Morris, 501-748-5342
scott.l.morris@uniti.com
Originally published on Guiding Stars Health & Nutrition News
Long gone are the days when “consulting Dr. Google” was the only online tool for quick information on health issues. These days there are many free, Artificial Intelligence (AI) powered online agents (or “chatbots”) available to anyone with internet access or a smartphone. Looking for a heart-healthy meal plan? Want to estimate the calories in your lunch just using a photo of your plate? Need a list of the best food sources of magnesium? If you’ve got a question, AI will supply an answer in mere seconds. But is it quality information? It can be hard to tell. Here are our top suggestions for vetting nutrition information gleaned from an AI source.
Just like in “real life,” it’s always best to get a second opinion when it comes to important health-related questions. Compare the information you get from an AI summary to what you find from a trusted and reputable source. Some examples of places you can cross-reference with include:
In general, AI health information isn’t known for a high degree of accuracy. For example, a recent systematic review of multiple studies found that AI is pretty good at answering simple questions. But more involved tasks, like constructing meal plans for people with multiple health conditions (like type 2 diabetes and a food allergy), increase inaccuracies. Let’s say you stick to simple queries, such as “How can I add more beans to my diet?” In that case, you’re fine to get a quick AI answer and see if any ideas appeal to you. But then there are more complicated or important questions, like “Will my hair and nails supplement interfere with my medications?” For those kinds of searches, you probably don’t want to rely on an AI answer as the final word.
Convenience isn’t a replacement for critical thinking, and higher-stakes health issues deserve professional guidance. Do more research and ask your doctor or dietitian—they actually know you.
AI responses to health and nutrition questions often don’t provide source information. And without the evidence, you can’t check to see what the truth really is. It’s not that AI sets out to lie about things, it’s more that the process of reviewing and distilling large quantities of information doesn’t guarantee high-quality results. Not all sources of nutrition information deserve the same amount of consideration. And scientific nuance is not AI’s strong suit.
In addition, AI agents don’t review all published research before answering—they simply don’t have access to everything published. So you need to specifically ask AI for answers based on published, scientific evidence, and for links to the references. Then click those links and check those reference articles.
You should also be aware that AI sometimes “hallucinates” references. Despite looking like real scientific references, they are made up! It’s easy to check and see if the studies cited actually exist—and confirm if what AI told you is correct. Yes, it takes more time than just reading an AI overview and going with whatever it says. But we’re talking about your health. And if you can’t trust that you’re getting quality information, what’s the point of asking?
Nutrition is a very context-dependent science. General or “cookie-cutter” nutrition guidance isn’t necessarily appropriate for every individual. You are unique. Consider your age, gender, family history of health issues, specific medical diagnoses, and medication list. And don’t forget your possible allergies, food preferences, budgetary considerations, and more. All of these factors play into whether certain nutrition advice will apply to you, so the research AI used to create that nutrition advice may not be relevant to you.
So once you look at what AI delivered, take a moment and ask yourself, “Does this information actually apply to my situation?” If not, perhaps change the question you asked and give more information about your situation or your unique conditions. Then the AI agent should be able to give you more targeted and appropriate advice. And as always, double check with your doctor before changing anything with your diet, supplements, or medications.
Guiding Stars is an objective, evidence-based, nutrition guidance program that evaluates foods and beverages to make nutritious choices simple. Products that meet transparent nutrition criteria earn a 1, 2, or 3 star rating for good, better, and best nutrition. Guiding Stars can be found in more than 2,000 grocery stores, in Circana’ Attribute Marketplace, and through the Guiding Stars Food Finder app.
QUEBEC CITY–(BUSINESS WIRE)–iA Financial Group (TSX: IAG) announces the addition of five new investment options to its segregated fund lineup. These additions further strengthen a lineup built on strong investment performance, diversity, innovation and responsiveness to the evolving needs of advisors and clients. “The expansion of our segregated fund offering reflects our commitment to delivering innovative, diversified investment solutions that evolve alongside the needs of investors and adv
SAN FRANCISCO–(BUSINESS WIRE)– #AndersenConsulting–Andersen Consulting expands its digital and business transformation capabilities through a Collaboration Agreement with John Keells IT (JKIT).
TEMPE, Ariz.–(BUSINESS WIRE)–VisualVault launches AI-powered licensing software to help governments speed approvals and boost local economies.
QUÉBEC–(BUSINESS WIRE)–iA Groupe financier (TSX: IAG) annonce l’ajout de cinq nouvelles options d’investissement à sa gamme de fonds distincts. Ces nouvelles options d’investissement viennent renforcer une gamme déjà reconnue pour sa performance, sa diversité, son innovation et sa capacité à évoluer avec les besoins des conseillers et des clients. « La bonification de notre offre de fonds distincts reflète notre engagement à fournir aux investisseurs et aux conseillers des solutions toujours
